BRIGHT GREEN EMBARKS ON MAJOR PARTNERSHIP WITH BENUVIA PHARMACEUTICALS. WILL SUPPLY PHARMA EXPERT WITH AMERICAN MADE RAW MATERIALS FROM ITS INDUSTRY LEADING AND DEA-APPROVED SCH I & II DRUG FACILITY.
Bright Green (Nasdaq: BGXX) has signed a letter of intent to supply DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a leader in pharmaceutical cannabinoids and psychedelic molecules. This partnership aims to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients (APIs) for US and global markets.
Bright Green is positioning itself as a leading domestic supplier of DEA-controlled, plant-based raw materials for cannabinoid, psychedelic, and opioid-based drugs in the USA. The company meets the DEA's high national standards for Schedule I & II drug cultivation and manufacturing, setting the stage for strong performance in 2025.
Bright Green (Nasdaq: BGXX) ha firmato una lettera di intenti per fornire estratti di marijuana approvati dalla DEA e psichedelici a base vegetale a Benuvia Operations, un leader nei cannabinoidi farmaceutici e nelle molecole psichedeliche. Questa partnership mira a produrre Ingredienti Farmaceutici Attivi (API) di grado farmaceutico cGMP fabbricati a livello nazionale per i mercati statunitensi e globali.
Bright Green si sta posizionando come un fornitore nazionale leader di materie prime a base vegetale controllate dalla DEA per farmaci a base di cannabinoidi, psichedelici e oppioidi negli USA. L'azienda soddisfa gli elevati standard nazionali della DEA per la coltivazione e la produzione di farmaci di Programma I e II, preparando il terreno per una forte performance nel 2025.
Bright Green (Nasdaq: BGXX) ha firmado una carta de intenciones para suministrar extractos de marihuana aprobados por la DEA y psicodélicos a base de plantas a Benuvia Operations, un líder en cannabinoides farmacéuticos y moléculas psicodélicas. Esta asociación tiene como objetivo producir Ingredientes Farmacéuticos Activos (API) de grado farmacéutico cGMP fabricados en el país para los mercados de EE. UU. y globales.
Bright Green se está posicionando como un proveedor nacional líder de materias primas a base de plantas controladas por la DEA para medicamentos basados en cannabinoides, psicodélicos y opioides en EE. UU. La empresa cumple con los altos estándares nacionales de la DEA para el cultivo y la producción de drogas de las Programas I y II, preparando el camino para un sólido rendimiento en 2025.
브라이트 그린 (Nasdaq: BGXX)는 DEA 승인을 받은 대마초 추출물 및 식물 기반 환각제를 제약 칸나비노이드 및 환각 분자의 선두 업체인 벤비비아 운영에 공급하기 위한 의향서를 체결했습니다. 이 파트너십의 목적은 미국 및 글로벌 시장을 위한 국내 제조 cGMP 제약 등급의 활성 제약 성분(API)을 생산하는 것입니다.
브라이트 그린은 미국 내 DEA에 의해 통제되는 식물 원자재의 선도적인 국내 공급업체로 자리매김하고 있습니다. 이 회사는 스케줄 I 및 II 약물의 재배 및 생산에 대한 DEA의 높은 국가 기준을 충족하여 2025년 강력한 성과를 위한 토대를 마련하고 있습니다.
Bright Green (Nasdaq: BGXX) a signé une lettre d'intention pour fournir des extraits de marijuana approuvés par la DEA et des psychédéliques à base de plantes à Benuvia Operations, un leader dans les cannabinoïdes pharmaceutiques et les molécules psychédéliques. Ce partenariat vise à produire des ingrédients pharmaceutiques actifs (API) de qualité pharmaceutique cGMP fabriqués localement pour les marchés américain et mondial.
Bright Green se positionne comme un fournisseur national leader de matières premières d'origine végétale contrôlées par la DEA pour les médicaments à base de cannabinoïdes, psychédéliques et opioïdes aux États-Unis. L'entreprise respecte les élevés standards nationaux de la DEA pour la culture et la fabrication de médicaments de l'annexe I et II, préparant ainsi le terrain pour une performance solide en 2025.
Bright Green (Nasdaq: BGXX) hat einen Absichtserklärung unterzeichnet, um von der DEA genehmigte Marihuana-Extrakte und pflanzliche Psychedelika an Benuvia Operations, einen führenden Anbieter von pharmazeutischen Cannabinoiden und psychotropen Molekülen, zu liefern. Diese Partnerschaft zielt darauf ab, inländisch produzierte cGMP-pharmazeutische Wirkstoffe (API) für die US-amerikanischen und globalen Märkte herzustellen.
Bright Green positioniert sich als führender inländischer Anbieter von von der DEA kontrollierten, pflanzenbasierten Rohstoffen für cannabinoid-, psychedelische und opioidhaltige Medikamente in den USA. Das Unternehmen erfüllt die hohen nationalen Standards der DEA für den Anbau und die Herstellung von Drogen der Kategorien I und II und bereitet sich auf eine starke Leistung im Jahr 2025 vor.
- Partnership with Benuvia Operations to supply DEA-approved marijuana extracts and plant-based psychedelics
- Potential to become a leading domestic supplier of DEA-controlled, plant-based raw materials
- Meets DEA's high national standards for Schedule I & II drug cultivation and manufacturing
- Positioned for strong performance in 2025
- Operations have not yet begun, indicating potential delays in revenue generation
- Dependence on regulatory approvals and compliance with DEA standards
Insights
This partnership marks a significant milestone for Bright Green (BGXX), potentially boosting its revenue streams and market position. The agreement to supply DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations demonstrates Bright Green's unique competitive advantage in the pharmaceutical supply chain. This move could enhance BGXX's financial outlook, especially considering the projected
Investors should note that while this news is promising, it's important to monitor the execution of this partnership and its impact on Bright Green's financials. The company's ability to meet regulatory standards and scale production will be key factors in determining long-term success. With a new round of fundraising mentioned, investors should also watch for potential dilution effects on share value.
This partnership between Bright Green and Benuvia is a game-changer for the US pharmaceutical industry. It addresses a critical need for domestically-sourced, high-quality raw materials for Schedule I & II drugs. The ability to produce these materials in compliance with GACP, GMP and DEA standards within the USA is a significant competitive advantage.
This collaboration could accelerate drug development in areas like cannabinoid and psychedelic-based therapies, potentially leading to breakthrough treatments for various conditions. However, the success of this venture will depend on Bright Green's ability to consistently meet the stringent quality and regulatory requirements of the pharmaceutical industry. The partnership's impact on drug pricing and availability in the US market will be interesting to observe.
This partnership highlights Bright Green's unique regulatory position as one of the few companies authorized by the US government to handle Schedule I and II controlled substances. Their compliance with DEA standards and New Mexico Board of Pharmacy regulations gives them a significant legal advantage in this highly regulated market.
However, investors should be aware of the complex legal landscape surrounding controlled substances. While Bright Green operates legally at the federal level, changes in administration or policy could impact the regulatory environment. Additionally, the company must navigate varying state laws and international regulations for potential exports. Ongoing legal due diligence will be important to maintain compliance and mitigate risks in this evolving legal framework.
GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use.
This completely homegrown agreement signals Bright Green’s ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Green’s unique position to produce Schedule I & II raw materials in full compliance with Good Agricultural and Collection Practices (GACP), Good Manufacturing Practices (GMP), and the DEA, all within the USA, to produce domestically manufactured cGMP pharmaceutical-grade Active Pharmaceutical Ingredients (“APIs”) for US and global markets.
Bright Green sees this as yet another step towards becoming the leading domestic supplier of DEA controlled, plant-based raw materials to produce cannabinoid, psychedelic and opioid based drugs in the USA. With a new round of fundraising and supply agreements in the works, Bright Green is positioned for a strong performance in 2025.
The Drug Enforcement Administration (DEA) just completed its annual operational procedures for all its Schedule I & II drug cultivation and manufacturing in July. Bright Green meets this high national standard and is now one step closer to beginning operations and supplying the pharmaceutical world with the materials it needs to innovate.
ABOUT BRIGHT GREEN CORPORATION
Bright Green is one of the few companies authorized by the US government and the New Mexico Board of Pharmacy to grow, manufacture, and sell, legally under federal and state law, Schedule I and II plant-based drugs for research, pharmaceutical applications, and affiliated export. Bright Green’s approval from the U.S. Drug Enforcement Administration gives them the opportunity to advance their vision of improving quality of life through the opportunities presented by cannabis and other plant based derived therapies and more. To learn more, visit www.brightgreen.us
ABOUT BENUVIA
Benuvia Operations, LLC is a pioneering leader in the research, development, and commercialization of innovative pharmaceutical products across a wide range of therapeutic areas. Benuvia is committed to improving patient outcomes through rigorous scientific study and quality manufacturing practices. With FDA registration, DEA licensing, and cGMP certification, Benuvia operates at the forefront of the pharmaceutical industry. Benuvia's flagship product, SYNDROS, is an FDA-approved medication used for the treatment of anorexia associated with weight loss in patients with AIDS and for managing chemotherapy-induced nausea and vomiting. To learn more, visit www.benuvia.com.
Media Inquiries & Investor Relations Contact
ir@brightgreen.us
FAQ
What is the significance of Bright Green's partnership with Benuvia Pharmaceuticals?
What products will Bright Green (BGXX) supply to Benuvia Pharmaceuticals?
How does Bright Green's DEA approval impact its business prospects?
What is Bright Green's (BGXX) current operational status as of August 2024?
